DexCom (DXCM) - FREE Research Report

Kahn Barbara who is Director at DexCom sold 1,500 shares at $32.63 on Dec. 6, 2013. Following this transaction, the Director owned 49,263 shares meaning that the stake was reduced by 2.95% with the 1,500-share transaction.

The shares most recently traded at $34.54, up $1.91, or 5.54% since the insider transaction. Historical insider transactions for DexCom go as follows:

  • 4-Week # shares sold: 46,568
  • 12-Week # shares sold: 46,568
  • 24-Week # shares sold: 46,568

The average volume for DexCom has been 619,200 shares per day over the past 30 days. DexCom has a market cap of $2.5 billion and is part of the health care sector and health services industry. Shares are up 154.97% year-to-date as of the close of trading on Friday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently there are 8 analysts that rate DexCom a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings rates DexCom as a sell. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full DexCom Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Income-REIT New Residential Investment Looks Worth It

Here Are the Best Bourses for International ETFs in 2017

3 Stocks With Dividend Yields of More Than 10%

Invesco Mortgage Capital (IVR) Is Today's Strong On High Volume Stock

What To Sell: 3 Sell-Rated Dividend Stocks ENLK, WPG, IVR